Clinical trial NCT04515459: Efficacy of Pre-operative Prehabilitation in Patients With Limb Sarcoma
Official title: Efficacy of Pre-operative Prehabilitation in Patients With Limb Sarcoma
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Sarcoma
Keywords: Bone sarcoma
Soft-tissue sarcoma
Pre-operative prehabilitation
Lead sponsor: Institut Claudius Regaud
Sponsor class: OTHER
First posted: 2020-08-17
Enrollment: 53
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This Phase II feasibility study, prospective, interventional, monocentric aiming to assess the interest of pre-operative rehabilitation in patients treated for bone or soft-tissue sarcoma of the limbs.

This protocol will be based on the realisation of a surgical prehabilitation program adapted to the patient. This strategy will involve a team of several health professionals: rehabilitation doctor, physiotherapist, occupational therapist, specialised nurse, dietician and adapted physical activity teacher.

The aim of an adapted surgical prehabilitation program is to improve the functional recovery of the treated limb and the patient's autonomy after surgery.

Each patient will be followed until 24 months post surgery.


Eligibility criteria: Inclusion Criteria:

1. Age \> or = 16 years old.
2. Patient with a diagnosis of bone or soft-tissue sarcoma confirmed by the "Réseau de Relecture en Pathologie Sarcomateuse (RRePS)"
3. Tumour localized in the lower or upper limb.
4. Localized or metastatic disease (in case of metastatic disease, the optimal surgical treatment for the primary tumor must be performed).
5. Indication of neoadjuvant treatment (radiotherapy and/or chemotherapy) according to the Multidisciplinary Concertation Meeting.
6. Inclusion before the initiation or during neoadjuvant treatment. In both cases, surgery must be scheduled between 6 and 10 weeks after inclusion, to permit the completion of the surgical prehabilitation.
7. Patient must provide written informed consent prior to any study-specific procedure. For minor patients, the holder(s) of parental authority must sign the informed consent and the patient's assent must be obtained.
8. Patient affiliated to the French social security system.

Exclusion Criteria:

1. Metastatic disease without optimal surgery planned of the primary tumour.
2. Any disease or medical condition that could interfere with study procedure, or that could, according to the judgment of investigator, expose the patient to an unacceptable risk.
3. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).
4. Any psychological, familial, geographic or social situation preventing compliance with the medical monitoring and/or with study procedure.
5. Pregnant or breastfeeding patient.

Primary outcomes:
measure: Rate of patients with a MSTS score (Musculoskeletal Tumor Rating Scale) greater than 75% at 24 months post-surgery.
timeFrame: 26 months for each patient.
Secondary outcomes:
measure: Quality of life using the Quality Of Life Questionnaire Core 30 (QLQ-C30).
timeFrame: 26 months for each patient.
measure: Anxiety using the Hospital Anxiety and Depression Scale (HADS).
timeFrame: 26 months for each patient.
measure: Depression using the Hospital Anxiety and Depression Scale (HADS).
timeFrame: 26 months for each patient.
measure: The patient functionality will be evaluated using the Tinetti's test from OTE1 to OTE8.
timeFrame: 26 months for each patient.
measure: The patient functionality will be evaluated using the 6-min walk test from OTE1 to OTE8.
timeFrame: 26 months for each patient.
measure: The patient functionality will be evaluated using the New Functional Ambulation Classification test from OTE1 to OTE8.
timeFrame: 26 months for each patient.
measure: The patient functionality will be evaluated using the Box and Block Test from OTE1 to OTE8.
timeFrame: 26 months for each patient.
measure: The patient functionality will be evaluated using the Frenchay Arm Test from OTE1 to OTE8.
timeFrame: 26 months for each patient.
measure: The patient functionality will be evaluated using the Visual Analog Scale from OTE1 to OTE8.
timeFrame: 26 months for each patient.
measure: The patient functionality will be evaluated using the Ricci and Gagnon's Score from OTE1 to OTE8.
timeFrame: 26 months for each patient.
Other outcomes:
Locations:
city: Toulouse
country: France
facility: Institut Universitaire du Cancer de Toulouse - Oncopole
Study officials:
References: